510(k) · Cleared
Recalled · Class II · 2022Vidas Estradiol II (E2II) Assay
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Biomerieux Vitek, Inc. · CHP Radioimmunoassay, Estradiol
Cleared on Feb 6, 1996 after a 56-day review. FDA has not posted a summary or statement for it, so its predicates are not known. It has been recalled 2 times.
- Decided
- Feb 6, 1996
- Review
- 56 days
- Class
- Class I
- Product code
- CHP
- Recalls
- 2
- Predicates
- 0
FDA has not posted a summary or statement for it, so its predicates are not known.
Sources: FDA 510(k) database (decision fields), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in CHP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against?
FDA has not posted a summary or statement for it, so its predicates are not known.
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
Recalls of this device
| Date | Class | Recall | Root cause | Reason |
|---|---|---|---|---|
| Nov 9, 2022 | Class II | Z-0867-2023 | Storage | As the temperature and time out of range was exceeded, product performances cannot be guaranteed |
| Mar 17, 2017 | Class II | Z-1801-2017 | Device Design | Fulvestrant cross reacts with the VIDAS Estradiol II immunoassay and may cause falsely elevated estradiol results in patients treated with Fulvestrant. |
No ancestor or descendant has a Class I recall.
How does its category compare?
All CHP devicesCHP Radioimmunoassay, Estradiol: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · CHP
FDA has decided no CHP device since 2007.
Median 510(k) review, days · CHP
Too few CHP 510(k)s in any year since 2007 to give a median.
Recalls per year · CHP
7in 2022
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · CHP
84in 2025
MAUDE reports naming product code CHP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 1 | 0 |
| 2008 | 0 | — | 0 | 1 |
| 2009 | 0 | — | 0 | 9 |
| 2010 | 0 | — | 1 | 12 |
| 2011 | 0 | — | 0 | 10 |
| 2012 | 0 | — | 0 | 15 |
| 2013 | 0 | — | 0 | 4 |
| 2014 | 0 | — | 0 | 12 |
| 2015 | 0 | — | 0 | 18 |
| 2016 | 0 | — | 1 | 29 |
| 2017 | 0 | — | 1 | 39 |
| 2018 | 0 | — | 1 | 38 |
| 2019 | 0 | — | 0 | 36 |
| 2020 | 0 | — | 0 | 135 |
| 2021 | 0 | — | 1 | 43 |
| 2022 | 0 | — | 7 | 61 |
| 2023 | 0 | — | 0 | 60 |
| 2024 | 0 | — | 0 | 65 |
| 2025 | 0 | — | 0 | 84 |
| 2026 | 0 | — | 0 | — |
https://510kreport.com/device/K955647 · printed Nov 6, 2026
Cite this page
510(k) Report. “K955647: Vidas Estradiol II (E2II) Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K955647
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Page last updated Nov 3, 2026